Palladio Biosciences, Inc., is a Centessa company. Their first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys.  It is a life-limiting, chronic and progressive disease.

Biotechnology

Palladio Biosciences

Alex Martin

Amy Murnane

Linda C. Hogan

Milena Kanova

Marcus Abraitis

Lorenzo Pellegrini

Ron Dadino

Neil H. Shusterman

Palladio Biosciences' Leadership Team includes Neil H. Shusterman and 7 others.

Leadership Team

��

Leadership Team

About

Team members

��������

Leadership Team

About

Team members

��